Current financial headlines
Financial news from across the world, newest first. Choose a country or market group, open the source, or continue into the company data.
Chronological news
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Indivior Pharmaceuticals (INDV) has agreed to merge with Supernus Pharmaceuticals, forming a new entity named Supernus, Inc., with shared leadership from both companies. The merger will introduce a significant debt and a special dividend, impacting the combined company's financial structure and requiring close monitoring …
Sharemaestro market context Trend signal active 52 weeks +65.5% · Next-week setup positive 55.1%Kamada Ltd. Q2 2026 Earnings Call Summary - Moby Strategic Growth Pillars and Operational Execution Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap …
Cronos Group Inc. (CRON) shares rose 2.92% on Wednesday, closing at $3.17, outperforming a mixed market session. The NASDAQ Composite Index gained 0.54%, while the Dow Jones Industrial Average fell 0.04%. This marks the second consecutive day of gains for Cronos Group stock.
This article provides analyst insights, price targets, and recommendations for UNITED THERAPEUTICS CORP (UTHR.MX). It lists recent upgrades and downgrades from various financial institutions like RBC Capital, JP Morgan, B of A Securities, and Wells Fargo, detailing their maintained or changed ratings. The stock …
BioCryst Pharmaceuticals reported strong Q2 2026 results, with total revenue up 45% year-over-year to $218.3 million and ORLADEYO net revenue increasing 10% to $158.2 million. The company is transitioning to an external innovation model, closing its Birmingham research facility, and has launched its pediatric …
Aquestive Therapeutics, Inc. (AQST) published its Q2 2026 earnings call presentation on August 12, 2026. The company reported an EPS of -$0.07, beating estimates by $0.05, and revenue of $13.82 million, a 38.15% year-over-year increase, beating estimates by $2.26 million. This presentation provides details …
Neurocrine Biosciences stock experienced a dip after reports emerged of deaths and severe complications potentially linked to its drug Vykat XR, used for Prader-Willi syndrome. The FDA's adverse event data revealed seven deaths and over 100 serious events, primarily involving edema, respiratory, and cardiac …
Talphera, Inc. announced its second-quarter 2026 financial results and provided a corporate update, highlighting that its NEPHRO CRRT clinical study of nafamostat is 75% enrolled and expected to be completed this year. The company noted that draft 2026 KDIGO guidelines now include nafamostat as …
Davis Selected Advisers has reported a beneficial ownership of 75,232,254 shares, representing a 6.5% stake in Viatris Inc. The firm holds sole voting power over 72,567,897 shares and sole dispositive power over all 75,232,254 shares. This disclosure, filed as a Schedule 13G/A, indicates Davis …
Amneal Pharmaceuticals AMRX completed its acquisition of Kashiv BioSciences on Monday, creating an integrated global biosimilars platform spanning research, development, manufacturing and commercialization. The deal broadens Amneal's biosimilar capabilities as it seeks more consistent launches. The investment case still depends on integration, regulatory execution …
Sharemaestro market context Trend signal active 52 weeks +92.0% · Next-week setup positive 57.9%Amneal Pharmaceuticals AMRX enters the second half of 2026 with higher guidance and a broader product pipeline. The company is expanding complex generics, biosimilars and specialty medicines while adjusted earnings and EBITDA improve. The trade-off is clear. Rytary has lost exclusivity, generic pricing remains …
Sharemaestro market context Trend signal active 52 weeks +92.0% · Next-week setup positive 57.9%Amneal Pharmaceuticals AMRX shares have gained 44.8% over the past 12 weeks, putting the durability of the advance in focus. The rally has coincided with better operating results and a higher 2026 outlook. The next leg will depend on whether earnings growth, new launches …
Sharemaestro market context Trend signal active 52 weeks +92.0% · Next-week setup positive 57.9%Liquidia topped Wall Street's second-quarter expectations Wednesday as sales of its lung disease treatment, Yutrepia, grew by double digits. Continue Reading
Sharemaestro market context Trend signal active 52 weeks +247.7% · Next-week setup positive 55.5%Investors with an interest in Medical - Products stocks have likely encountered both Prestige Consumer Healthcare (PBH) and Stryker (SYK). But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. Everyone has their own …
Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Manager of Investor Relations - Stephanie Diaz President and Chief Executive Officer - Paul Josephs Chief Financial Officer - Ryan Lake Full Conference Call Transcript Operator: Good morning, …
Shares of Alkermes ALKS have risen 26.5% in the past three months, driven by strong sales growth across its proprietary product portfolio and continued progress in its clinical pipeline. Alkermes' proprietary products include Vivitrol for alcohol and opioid dependence, Aristada for schizophrenia, Lybalvi for …
Sharemaestro market context Trend signal active 52 weeks +69.3% · Next-week setup negative 42.9%Reports have emerged of seven deaths and 100 serious adverse events potentially linked to Neurocrine Biosciences’ Prader-Willi syndrome drug, Vykat, prompting concerns among clinicians and patient advocacy groups. Concurrently, Aardvark Therapeutics terminated its Phase 3 trial for ARD-101 for the same condition due to …
Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Executive Chairman and Chief Executive Officer - Miguel Martin Chief Financial Officer - Simona King Director of Strategic Finance and Investor Relations - Kevin Niland Full Conference Call …
Key Points Interested in Kamada Ltd.? Here are five stocks we like better. Record results: Second-quarter revenue rose 23% year over year to $54.9 million, while first-half revenue increased 13% to $100.2 million. First-half adjusted EBITDA grew 14% to $25.7 million, with a 26% …
Tango Therapeutics TNGX incurred a loss of 37 cents per share in the second quarter of 2026, wider than the Zacks Consensus Estimate of a loss of 31 cents. The company had reported a loss of 35 cents per share in the year-ago quarter. …
Image source: The Motley Fool. DATE Tuesday, Aug. 4, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Head of Investor Relations - Susan Mesco Chief Executive Officer - Frank Lee Chief Commercial Officer - Brendan Teehan Chief Financial Officer - Shawn Cross Chief Administrative Officer …
Kamada Ltd. (NASDAQ:KMDA) reported strong Q2 2026 results, with adjusted earnings of $0.24 per share significantly exceeding the $0.11 consensus estimate, driven by a 23% revenue increase to $54.9 million. The company's Proprietary Products segment was a key growth driver, and management provided a …
Evotec SE announced a notification of major holdings, indicating that The Goldman Sachs Group, Inc. has acquired or disposed of shares with voting rights. As of August 6, 2026, Goldman Sachs holds a total of 13.71% of voting rights in Evotec SE, an increase …
Collegium Pharmaceutical's Q2 earnings showed sales growth driven by its ADHD business, with Jornay PM revenue up 41% year-over-year, but overall revenue missed Wall Street estimates due to pricing pressure on the NUCYNTA pain franchise. Despite this, the company raised its full-year revenue guidance. …
Key Points Interested in Aquestive Therapeutics, Inc.? Here are five stocks we like better. Aquestive plans to resubmit Anaphylm's FDA application before the end of Q3 after revised packaging and instructions substantially reduced pouch-opening, film-tearing and administration errors in validation studies. Management is assuming …
Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Interim President and Chief Executive Officer - Albert Manzone Executive Vice President and Chief Financial Officer - Eduardo Bezerra VP Global Investor Relations - Eric Jacobson Full Conference …
Liquidia Corporation reported a Q2 2026 earnings miss with EPS of $0.74 against an estimated $0.76, but surpassed revenue expectations with $171.6
Kamada Ltd. reported record-high Q2 2026 results, surpassing Wall Street expectations with $0.16 EPS on $54.9 million revenue. The company achieved 23% year-over-year revenue growth and a 29% increase in adjusted EBITDA, driven by strong performance across its specialty plasma-derived products and disciplined expense …
Aquestive Therapeutics reported Q2 2026 revenue of $13.82 million, exceeding analyst estimates, but also posted a wider-than-expected loss of $0.18 per share due to an $11.7 million debt extinguishment charge. The company remains on track to resubmit its Anaphylm NDA to the FDA in …
Experts in Prader-Willi Syndrome have raised safety concerns regarding Neurocrine's drug Vykat XR, citing serious adverse events reported in patients. Post-marketing surveillance revealed reports of edema, respiratory and cardiac complications, and seven deaths linked to the drug as of July 31st, though no causal …
Emergent BioSolutions' Executive Vice President and Chief Growth Officer, Stephanie Duatschek, has reported her initial equity holdings, which include 197,416 shares of common stock and various employee stock options. Her holdings comprise 55,639 direct common shares and 141,777 unvested Restricted Stock Units (RSUs), with …
IQVIA Holdings Inc. IQV stock has rallied over the past three months. The company's shares have jumped 41.5%, outperforming the industry's 17.2% growth and the Zacks S&P 500 Composite's 3.4% uptick. 3-Month Share Price PerformanceZacks Investment Research Image Source: Zacks Investment Research Let us …
Neurocrine Biosciences announced the publication of KINECT-PRO™ Phase 4 study results, showing that INGREZZA® (valbenazine) capsules significantly improved patient-reported quality of life and daily functioning, alongside clinician-rated tardive dyskinesia (TD) movement severity. These improvements were seen across various patient demographics, including those with mild …
Search by ticker symbol or company name and select a result to open its chart.